Glioblastoma (GBM) is one of the most aggressive brain tumors, and typically exhibits hyper vascularity and marked heterogeneity. GBM constitutes a major clinical problem because of its high rate of recurrence and aggressive phenotype leading to extremely poor prognosis. Accordingly, it is often impossible to resect 100% of tumor mass during surgery and the left over tumor cells might become more aggressive and resistant to future therapies.
Although is growing evidence that chemotherapy plays an increasingly significant role in treatment of malignant gliomas, the benefit in survival improvement is not satisfactory. Mortality due to brain cancer has essentially remained unchanged in the last three decades. Therefore, it is important to explore and identify more efficient therapeutic strategies across the blood-brain tumor barrier (BBTB), coupled with an ability to image the true extent of drug delivery to the tumor for the treatment of malignant gliomas. A number of preclinical and clinical studies suggest that natural compounds such as curcumin may represent useful additions to therapeutic regimens of cancer patients.